Cellectar reports 8-year remission in lymphoma case study
Cellectar Biosciences (CLRB) reported an 8-year remission in a lymphoma patient treated with iopofosine I 131. The patient achieved complete response by day 85 and has shown no disease progression since. The company plans to submit findings for publication and is advancing a Phase 3 study in Waldenström macroglobulinemia, with FDA submission expected in 2027. Iopofosine I 131 has received several FDA designations for various cancer indications.
How this was made
The 30-second read
Why it matters
The case study provides tangible proof of concept, potentially accelerating investor enthusiasm ahead of the Phase 3 readout.
Market read
First public evidence of durable remission could lift CLRB stock and influence sentiment in the radiopharma niche.
What to watch
Regulatory timelines and the need for Phase 3 data remain uncertain; market may price in risk of later trial outcomes.
Background
Cellectar's iopofosine I‑131 has received multiple FDA designations (Breakthrough, Orphan, Fast Track). The company plans a Phase 3 trial in Waldenström macroglobulinemia with dosing in Q1 2027.
Ticker impact
Cellectar Biosciences reported an 8‑year complete remission in a lymphoma patient from a single dose of iopofosine I‑131, the first public disclosure of this case study.
potential upside as market prices in the long‑term efficacy and regulatory designations
First‑time disclosure of durable remission provides material new data for a biotech with limited prior efficacy evidence.
Market effects
strengthens outlook for radiopharmaceutical and targeted radio‑isotope therapies.
U.S. biotech investors may see increased interest; limited immediate global effect.
modest, confined to specialty oncology and radiopharma segments.
Counterpoint
The data is from a single patient; investors may view it as anecdotal and not indicative of broader trial success.
Key entities
- companyCellectar Biosciences Inc.
Developer of iopofosine I‑131, a phospholipid drug conjugate for targeted radiotherapy.
- executiveJames Caruso
President and CEO of Cellectar, quoted on the significance of the results.
